Literature DB >> 6392367

Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case-control study.

T Y Chuang, W Korkij, K Soltani, J Clayman, J Cook.   

Abstract

A case-control study was designed to assess the occurrence rate of primary diabetes mellitus (DM) in patients with bullous pemphigoid (BP) by retrospectively reviewing the records of our thirty histopathologically and immunopathologically proved cases of BP from the past 10 years. One hundred twenty patients were selected as controls, which included two names immediately before and two names immediately after each case of BP in our histopathology record book. The occurrence rate of primary DM prior to the administration of systemic corticosteroids was significantly higher in patients with BP than in the controls (20% and 2.5%, respectively; p = 0.004). Among patients over 50 years of age, this occurrence rate was again higher in patients with BP than in the controls (23% and 3.6% respectively; p = 0.02). This study suggests a higher than chance association of BP and primary DM.

Entities:  

Mesh:

Year:  1984        PMID: 6392367     DOI: 10.1016/s0190-9622(84)70266-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  The skin in diabetes mellitus.

Authors:  M J Goodfield; L G Millard
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

2.  Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.

Authors:  Arata Hibi; Yuto Kasahara; Yoshitaka Ishihara; Koichi Hata; Norihisa Hosokawa; Takahiko Nakagawa
Journal:  CEN Case Rep       Date:  2020-01-28

3.  Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study.

Authors:  Ezgi Aktaş Karabay; Aslı Aksu Çerman; İlknur Kıvanç Altunay
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2018-12-28

4.  A Retrospective Study of Patient-Reported Data of Bullous Pemphigoid and Mucous Membrane Pemphigoid From a US-Based Registry.

Authors:  Janet Lee; Kristina Seiffert-Sinha; Kristopher Attwood; Animesh A Sinha
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

5.  Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients.

Authors:  Vera Barreto Teixeira; Rita Cabral; Maria Manuel Brites; Ricardo Vieira; Américo Figueiredo
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

6.  The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.

Authors:  Zrinka Bukvić Mokos; Mikela Petković; Anamaria Balić; Branka Marinović
Journal:  Croat Med J       Date:  2020-04-30       Impact factor: 1.351

7.  A survey of bullous diseases in a Turkish university hospital: clinicoepidemiological characteristics and follow-up

Authors:  Zekayi Kutlubay; Ayşegül Sevim Keçici; Uğur Çelik; Mehmet Cem Mat
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

8.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.